John D Ratliff Insider Trading $LH LABORATORY CORP OF AMERICA HOLDINGS
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for John D Ratliff.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of John D Ratliff. John D Ratliff is CEO, Covance Drug Development in LABORATORY CORP OF AMERICA HOLDINGS ($LH) and President and COO in Quintiles Transnational Holdings Inc. ($Q).
John D Ratliff in LABORATORY CORP OF AMERICA HOLDINGS
Industry: SERVICES-MEDICAL LABORATORIES [8071]
Position of John D Ratliff: CEO, Covance Drug Development
Holdings: 18,025 shares
Current Value: $2,340,727
Latest Transaction: Apr 05 2019
$LH Market Capitalization: $13.45B
$LH Previous Close: $129.86
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of John D Ratliff in LABORATORY CORP OF AMERICA HOLDINGS
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 05 2019 | LH | LABORATORY CORP OF ... | Ratliff John D | CEO, Covance Drug D ... | Option Exercise | M | 0.00 | 2,424 | 0 | 19,787 | |
| Apr 05 2019 | LH | LABORATORY CORP OF ... | Ratliff John D | CEO, Covance Drug D ... | Payment of Exercise | F | 156.68 | 1,084 | 169,841 | 16,941 | 18 K to 16.9 K (-6.01 %) |
| Apr 05 2019 | LH | LABORATORY CORP OF ... | Ratliff John D | CEO, Covance Drug D ... | Buy | M | 0.00 | 2,424 | 0 | 18,025 | 15.6 K to 18 K (+15.54 %) |
| Feb 13 2019 | LH | LABORATORY CORP OF ... | Ratliff John D | CEO, Covance Drug D ... | Option Exercise | M | 0.00 | 6,100 | 0 | 18,374 | |
| Feb 13 2019 | LH | LABORATORY CORP OF ... | Ratliff John D | CEO, Covance Drug D ... | Payment of Exercise | F | 144.29 | 1,973 | 284,684 | 14,792 | 16.8 K to 14.8 K (-11.77 %) |
| Feb 13 2019 | LH | LABORATORY CORP OF ... | Ratliff John D | CEO, Covance Drug D ... | Buy | M | 0.00 | 6,100 | 0 | 16,765 | 10.7 K to 16.8 K (+57.20 %) |
| Feb 11 2019 | LH | LABORATORY CORP OF ... | Ratliff John D | CEO, Covance Drug D ... | Option Exercise | M | 0.00 | 1,863 | 0 | 24,474 | |
| Feb 11 2019 | LH | LABORATORY CORP OF ... | Ratliff John D | CEO, Covance Drug D ... | Payment of Exercise | F | 147.46 | 556 | 81,988 | 10,665 | 11.2 K to 10.7 K (-4.95 %) |
| Feb 11 2019 | LH | LABORATORY CORP OF ... | Ratliff John D | CEO, Covance Drug D ... | Buy | M | 0.00 | 1,863 | 0 | 11,261 | 9.4 K to 11.3 K (+19.82 %) |
| Apr 05 2018 | LH | LABORATORY CORP OF ... | Ratliff John D | CEO, Covance Drug D ... | Option Exercise | A | 0.00 | 12,120 | 0 | 26,337 | |
| Feb 14 2018 | LH | LABORATORY CORP OF ... | Ratliff John D | CEO, Covance Drug D ... | Option Exercise | A | 0.00 | 4,390 | 0 | 14,217 | |
| Feb 14 2018 | LH | LABORATORY CORP OF ... | Ratliff John D | CEO, Covance Drug D ... | Option Exercise | A | 168.49 | 17,100 | 2,881,179 | 17,100 | |
| Feb 13 2018 | LH | LABORATORY CORP OF ... | Ratliff John D | CEO, Covance Drug D ... | Option Exercise | M | 0.00 | 6,100 | 0 | 9,827 | |
| Feb 13 2018 | LH | LABORATORY CORP OF ... | Ratliff John D | CEO, Covance Drug D ... | Payment of Exercise | F | 168.08 | 2,132 | 358,347 | 9,398 | 11.5 K to 9.4 K (-18.49 %) |
| Feb 13 2018 | LH | LABORATORY CORP OF ... | Ratliff John D | CEO, Covance Drug D ... | Buy | M | 0.00 | 6,100 | 0 | 11,530 | 5.4 K to 11.5 K (+112.34 %) |
| Feb 09 2018 | LH | LABORATORY CORP OF ... | Ratliff John D | CEO, Covance Drug D ... | Option Exercise | M | 0.00 | 1,863 | 0 | 15,927 | |
| Feb 09 2018 | LH | LABORATORY CORP OF ... | Ratliff John D | CEO, Covance Drug D ... | Payment of Exercise | F | 169.66 | 560 | 95,010 | 5,430 | 6 K to 5.4 K (-9.35 %) |
| Feb 09 2018 | LH | LABORATORY CORP OF ... | Ratliff John D | CEO, Covance Drug D ... | Buy | M | 0.00 | 1,863 | 0 | 5,990 | 4.1 K to 6 K (+45.14 %) |
| Feb 13 2017 | LH | LABORATORY CORP OF ... | Ratliff John D | CEO, Covance Drug D ... | Option Exercise | M | 0.00 | 6,100 | 0 | 17,790 | |
| Feb 13 2017 | LH | LABORATORY CORP OF ... | Ratliff John D | CEO, Covance Drug D ... | Payment of Exercise | F | 133.83 | 2,013 | 269,400 | 4,127 | 6.1 K to 4.1 K (-32.79 %) |
| Feb 13 2017 | LH | LABORATORY CORP OF ... | Ratliff John D | CEO, Covance Drug D ... | Buy | M | 0.00 | 6,100 | 0 | 6,140 | 40 to 6.1 K (+15,250.00 %) |
| Feb 09 2017 | LH | LABORATORY CORP OF ... | Ratliff John D | CEO, Covance Drug D ... | Option Exercise | A | 130.60 | 21,300 | 2,781,780 | 21,300 | |
| Feb 09 2017 | LH | LABORATORY CORP OF ... | Ratliff John D | CEO, Covance Drug D ... | Option Exercise | A | 0.00 | 5,590 | 0 | 23,890 | |
| Oct 05 2016 | LH | LABORATORY CORP OF ... | Ratliff John D | CEO, Covance Drug D ... | Option Exercise | A | 0.00 | 18,300 | 0 | 18,300 |
Page: 1